In these videos, Dr.

The 2024 Lung Cancer OncTalk was a live, virtual, interactive patient education event presented in December 2024, moderated by Dr. Ibiayi Dagogo-Jack, Assistant Professor of Medicine at Harvard Medical School and a Medical Oncologist at Massachusetts General Hospital, and joined by speakers: Dr. Misty Shields, Indiana University School of Medicine, Dr. Alissa Cooper, Memorial Sloan Kettering Cancer Center, Dr. Angel Qin, University of Michigan Rogel Cancer Center, and Dr. Julia Rotow, Harvard Medical School. 

Topics include:

This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University

Topics include:

- Myeloma 101: Facts and Fiction of the 'Myeloma Marathon'

- Updates in DLBCL

- Treatment Basics of Bone Marrow Transplant

- Frontline Therapies in Myelofibrosis

- Panel Discussions and a Question-and-Answer session

In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO.

To watch the complete playlist, click here. 

Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.

The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+. 

Para ver la playlist completa, de click aquí.